文献速递肾小球疾病

VALIGA大队列证据支持对IgA肾病局灶节段性肾小球硬化进行亚分类

Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
PubMed 文献 · Kidney Int · 2024-03-28

基于VALIGA队列1147例IgA肾病患者的活检样本,研究分析了足细胞病变与蛋白尿水平、肾脏结局及免疫抑制治疗反应的关系。S1病变见于70%的活检,亚分类为NOS、Adh、PH和tip病变后,可识别出蛋白尿逐渐升高、肾脏生存逐渐恶化的四个亚组;免疫抑制仅在蛋白尿最高的两个亚组中与更好结局相关,倾向性分析显示糖皮质激素显著降低复合结局的时间依赖性风险。

要点

  • S1病变见于70%的IgA肾病活检,亚分类可区分不同蛋白尿和肾脏生存的亚组。
  • 伴足细胞肥大和单纯粘连的S1病变可能反映对糖皮质激素有反应的活性病变。
  • 免疫抑制治疗仅在蛋白尿最高的两个S1亚组中与更好结局相关。

核心结论

  • VALIGA队列证据支持对IgA肾病中的S1病变进行亚分类,以区分活动性与慢性病变并指导免疫抑制治疗决策。

研究设计与样本

  • 基于VALIGA研究队列,纳入1147例IgA肾病患者,对所有活检评估FSGS病变亚型,采用卡方自动交互检测法识别蛋白尿亚组,并用倾向性分析评估免疫抑制与结局的关系。

主要发现

  • S1病变见于70%的活检,NOS病变44%、Adh 59%、PH 13%、tip病变3%,病变间有较多重叠。
  • 识别出四个亚组,蛋白尿从低到高依次为:S1无NOS、S1有NOS但无Adh/PH、S1有NOS和Adh但无PH、S1有NOS和PH,四组肾脏生存逐渐恶化。
  • 免疫抑制仅在蛋白尿最高的两个亚组中与更好结局相关。
  • 在这两个亚组中,调整临床和病理因素后的倾向性分析显示,糖皮质激素显著降低复合结局的时间依赖性风险。

关键数值与推荐

  • S1定义需存在NOS病变和/或Adh。
  • 复合结局定义为肾衰竭或估算肾小球滤过率下降50%。

临床怎么用

  • 对IgA肾病S1病变进行亚分类,有助于识别可能从糖皮质激素治疗中获益的活性病变患者,并避免对慢性病变患者过度免疫抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence from the Oxford IgA nephropathy (IgAN) cohort supports the clinical value of subclassifying focal segmental glomerulosclerosis lesions (S1). Using the larger Validation in IgA (VALIGA) study cohort, we investigated the association between podocytopathic changes and higher proteinuria, kidney outcome and response to immunosuppressive therapy. All biopsies were evaluated for glomeruli with segmental capillary occlusion by matrix ("not otherwise specified", NOS lesion), simple capsular adhesion without capillary occlusion (Adh), tip lesions, and podocyte hypertrophy (PH). S1 required a NOS lesion and/or Adh. A Chi-Squared Automatic Interaction Detection method was used to identify subgroups of FSGS lesions associated with distinctive proteinuria at biopsy. We assessed survival from a combined event (kidney failure or 50% decline in estimated glomerular filtration rate). Finally, we evaluated within each subgroup if immunosuppression was associated with a favorable outcome using propensity analysis. In 1147 patients, S1 was found in 70% of biopsies. Subclassification found NOS lesions in 44%, Adh in 59%, PH in 13%, and tip lesions in 3%, with much overlap. Four subgroups were identified with progressively higher proteinuria: from lowest, S1 without NOS, S1 with NOS but without Adh/PH, to highest, S1 with NOS and Adh but without PH, and S1 with NOS and PH. These four subgroups showed progressively worse kidney survival. Immunosuppression was associated with a better outcome only in the two highest proteinuria subgroups. Propensity analysis in these two groups, adjusted for clinical and pathological findings, found a significantly reduced time-dependent hazard of combined outcome with corticosteroids. Podocyte hypertrophy and glomeruli with simple adhesions appeared to reflect active lesions associated with a response to corticosteroids, while other S1 lesions defined chronicity. Thus, our findings support subclassifying S1 lesions in IgAN.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Bellur SS, Troyanov S, Vorobyeva O, et al. Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int. 2024. PMID: 38554992. doi:10.1016/j.kint.2024.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。